SB-267268

N/A

Report date: 2025/03/18 15:07:33
NME

Base Information

Drug NameSB-267268
Drug Alias NameSB-267268
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonistsIntegrin alpha-V/beta-5 antagonists
TargetsIntegrin alpha-V/beta-3Integrin alpha-V/beta-5
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A